6b907244-c173-4e29-a163-24258a430477
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.600
- IL6_JAK_STAT3_SIGNALING+0.500
- INTERFERON_ALPHA_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- INFLAMMATORY_RESPONSE+0.300
- TNFA_SIGNALING_VIA_NFKB+0.300
- KRAS_SIGNALING_DN+0.200
- KRAS_SIGNALING_UP+0.200
- COMPLEMENT+0.100
- IL2_STAT5_SIGNALING+0.100
Top 10 suppressed
- MYC_TARGETS_V2-0.600
- E2F_TARGETS-0.500
- GLYCOLYSIS-0.500
- MTORC1_SIGNALING-0.500
- OXIDATIVE_PHOSPHORYLATION-0.500
- PROTEIN_SECRETION-0.500
- ADIPOGENESIS-0.400
- CHOLESTEROL_HOMEOSTASIS-0.400
- DNA_REPAIR-0.400
- FATTY_ACID_METABOLISM-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s0112296 | — | — | 0.957 |
| 2 | 362a2015-1791-4934-be81-df39540b38ff | — | — | 0.950 |
| 3 | e07c111b-da6e-4743-9351-77491153bec4 | — | — | 0.940 |
| 4 | be8d8236-4ebc-46de-a4fd-a901fec1cdce | — | — | 0.934 |
| 5 | TCGA-ZF-A9R7-01A-11R-A38B-07 | — | — | 0.924 |
| 6 | TCGA-AO-A0JC-01A-11R-A056-07 | — | D | 0.924 |
| 7 | MNG450 | — | — | 0.923 |
| 8 | TCGA-93-A4JO-01A-21R-A24X-07 | — | cohortA1 | 0.897 |
| 9 | ee0e68bf-7fa0-4edc-a9df-30a63c2db34a | — | — | 0.895 |
| 10 | s0122234 | — | — | 0.893 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |